US Patent

US9987274 — N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

Method of Use · Assigned to Ogeda SA · Expires 2034-03-28 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for treating and/or preventing hot flashes by administering a compound of Formula I or its solvate to a patient.

USPTO Abstract

A method for treating and/or preventing hot flashes, by administering, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.

Drugs covered by this patent

Veozah (FEZOLINETANT) · Astellas Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3622`	—	Veozah

Patent Metadata

Patent number: US9987274
Jurisdiction: US
Classification: Method of Use
Expires: 2034-03-28
Drug substance claim: No
Drug product claim: No
Assignee: Ogeda SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.